Topical fluticasone propionate lotion does not cause hpa axis suppression

Journal of Pediatrics

Volumn 149, Issue 3, 2006, Pages 378-382

  Hebert, Adelaide A ^a   Friedlander, Sheila Fallon ^a   Allen, David B ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE; HYDROCORTISONE; TETRACOSACTIDE;

ADRENAL FUNCTION; ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLICULITIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFANT; LOTION; MALE; OTITIS MEDIA; PAPULE; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; PURPURA; RASH; SCABIES; SKIN ATROPHY; STATISTICAL SIGNIFICANCE; STRIA; TELANGIECTASIA; TINEA; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ADMINISTRATION, CUTANEOUS; ANDROSTADIENES; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; EMULSIONS; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFANT; MALE; PITUITARY-ADRENAL SYSTEM;

EID: 33748186220     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.05.008     Document Type: Article

References (13)

1. Spencer C.M., and Wiseman L.R. Topical fluticasone propionate. a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Biodrugs 4 (1997) 318-334
2. Roeder A., Scaller M., Scäfer-Korting M., and Korting H.C. Safety and efficacy of fluticasoen propionate in the topical treatment of skin disease. Skin Pharmacol Physiol 18 (2005) 3-11
3. Berth Jones J.B., Damstra R.J., Golsch S., Livden J.K., van Hooteghem O., et al. Twice weekly fluticasone propionate added to emollient maintenance therapy to reduce risk of relapse in atopic dermatitis. randomised double blind, parallel group study. BMJ 326 (2003) 1367-1370
4. Hanifin J., Gupta A.K., and Rajagopalan R. intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 147 (2002) 1-10
5. Glazenburg E., Oranje A., Gerretsen A., and Oranje A. Twice weekly topical fluticasone propionate delays the time to relapse in children with chronic atopic dermatitis. J Eur Acad Dermatol Venereol 17 (2003) 184 (Abstract P2-42)
6. Bleehen S.S., Chu A.C., Hamann I., Holden C., Hunter J.A.A., and Marks R. Fluticasone propionate cream 0.05% in the treatment of atopic eczema. a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol 133 (1995) 592-597
7. Charman C.R., and Williams H.C. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 21 (2003) 193-200
8. Friedlander S.F., Hebert A., and Allen D.B. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 46 (2002) 387-393
9. Friedlander S.F., Hanifin J., and Glazenburg E.J. Three separate studies support the systemic safety of fluticasone propionate (FP) cream, ointment and lotion in the treatment of severe and extensive eczema in children as young as 3 months. J Am Acad Dermatol 121 (2003) (Abstract. 0334)
10. Dorin R.I., Qualls C.R., and Crapo L.M. Diagnosis of adrenal insufficiency. Ann Intern Med 139 (2003) 194-204
11. Chu A.C., and Munn S. Fluticasone propionate in the treatment of inflammatory dermatoses. Br J Clin Pract 49 (1995) 131-133
12. Wolkerstorfer A., Strobos M.A., Glazenburg E.J., Mulder P.G.H., and Oranje A.P. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol 39 (1998) 226-231
13. Westerhof W., Nieuweboer-Krobotova L., Mulder P., and Glazenburg E. Left-right comparison study of the combination of fluticasone propionate and UV-A vs either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 135 (1999) 1061-1066